Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13762174 | 1.00 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL8232225 | 1.00 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL30872937 | 1.00 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL685097 | 1.00 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL2055320 | 1.00 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL2108480 | 1.00 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL7721751 | 1.00 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1569371 | 1.00 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL21442028 | 1.00 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL680110 | 0.98 | CHRNB2 (0.36) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 267 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114958938-B | Preparation method of fused bicyclic proline methyl ester hydrochloride | 金达威生物技术(江苏)有限公司 | 2023-12-08 | — | — | CN | claimed |
| CN-117024511-A | Novel coronavirus-resistant peptidomimetic compound and preparation method thereof | 烟台大学 | 2023-11-10 | — | — | CN | claimed |
| CN-114605436-B | Intermediate of Pa Luo Weide or boceprevir, preparation method and application | 浙江九洲药业股份有限公司 | 2023-07-21 | — | — | CN | claimed |
| CN-114958938-A | Preparation method of fused bicyclic proline methyl ester hydrochloride | 金达威生物技术(江苏)有限公司 | 2022-08-30 | — | — | CN | claimed |
| CN-114605436-A | Intermediate of Peruvideb or Peruvivir, preparation method and application | 浙江九洲药业股份有限公司 | 2022-06-10 | — | — | CN | claimed |
| CN-114591299-A | Paroviride intermediate and preparation and application thereof | 雅本化学股份有限公司 | 2022-06-07 | — | — | CN | claimed |
| CN-114031543-A | Preparation method of intermediate of palovaried | 上海朴颐化学科技有限公司 | 2022-02-11 | — | — | CN | claimed |
| US-20100145069-A1 | PROCESS FOR THE PREPARATION OF 6,6-DIMETHYL-3-AZABICYCLO-[3.1.0]- HEXANE COMPOUNDS UTILIZING BISULFITE INTERMEDIATE | SCHERING CORPORATION (US) | 2010-06-10 | — | — | US | claimed |
| US-20260125421-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260109672-A1 | SARS-COV-2 MPRO INHIBITORS AND USES THEREOF | NXERA PHARMA UK LIMITED (GB) | 2026-04-23 | — | — | US | disclosed |
| US-20260015337-A1 | COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION | TRAWSFYNYDD THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4598937-A1 | SARS-COV-2 MPRO INHIBITORS AND USES THEREOF | Nxera Pharma UK Limited (GB) | 2025-08-13 | — | — | EP | disclosed |
| US-20250195495-A1 | RNA Virus Inhibitor Compounds and Uses Thereof | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2025-06-19 | — | — | US | disclosed |
| CN-120166994-A | Antiviral compounds | 豪夫迈·罗氏有限公司 | 2025-06-17 | — | — | CN | disclosed |
| US-20070004635-A1 | Method of treating interferon non-responders using HCV protease inhibitor | SCHERING CORPORATION | 2007-01-04 | — | — | US | disclosed |
| WO-2006130686-A2 | HCV PROTEASE INHIBITORS IN COMBINATION WITH FOOD | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130607-A2 | CONTROLLED-RELEASE FORMULATION USEFUL FOR TREATING DISORDERS ASSOCIATED WITH HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130687-A2 | LIVER/PLASMA CONCENTRATION RATIO FOR DOSING HEPATITIS C VIRUS PROTEASE INHIBITOR | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130553-A2 | HCV PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130688-A2 | COMPOUNDS FOR INHIBITING CATHEPSIN ACTIVITY | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004635-A1 | Method of treating interferon non-responders using HCV protease inhibitor | IFNAR1, IFNG, IRF3 | CHRNB2 4589/4885CHRNA4 3877/4885CHRNB4 4142/4885 |
| US-20260109672-A1 | SARS-COV-2 MPRO INHIBITORS AND USES THEREOF | ACE2, ACE, TMPRSS2 | CHRNB2 1397/4885CHRNA4 2961/4885CHRNB4 2884/4885 |
| US-20250195495-A1 | RNA Virus Inhibitor Compounds and Uses Thereof | NSUN3, EIF2AK2, NSUN2 | CHRNB2 4874/4885CHRNA4 4726/4885CHRNB4 4786/4885 |
| US-20260015337-A1 | COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION | ACE2, ACE, TMPRSS2 | CHRNB2 2428/4885CHRNA4 2621/4885CHRNB4 2656/4885 |
| US-20100145069-A1 | PROCESS FOR THE PREPARATION OF 6,6-DIMETHYL-3-AZABICYCLO-[3.1.0]- HEXANE COMPOUNDS UTILIZING BISULFITE INTERMEDIATE | DNMT1, TET2, TET3 | CHRNB2 2587/4885CHRNA4 1566/4885CHRNB4 2769/4885 |
| US-20260125421-A1 | ANTIVIRAL COMPOUNDS | ZC3HAV1, ZC3HAV1L, GTF3C3 | CHRNB2 4857/4885CHRNA4 4722/4885CHRNB4 4746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.